Get the Daily Brief
Latest Biotech News
Vedanta cuts staff, refocuses cash on VE303 phase‑3 push
Vedanta Biosciences said it significantly reduced headcount and refocused resources on advancing VE303, an eight‑strain live bacterial consortium aimed at preventing recurrent Clostridioides...
Novo Nordisk Foundation pledges up to $850M to scale European biotech incubator
The Novo Nordisk Foundation committed up to $850 million to expand Denmark’s BioInnovation Institute into a pan‑European innovation engine. The funding will let the institute broaden its support...
ImmunityBio CAR‑NK: durable complete responses in Waldenström’s lymphoma
ImmunityBio reported durable complete responses in an off‑the‑shelf CD19 CAR‑NK program for Waldenström’s macroglobulinemia, with responses sustained through seven and 15 months in the first...
Epkinly misses overall survival: AbbVie, Genmab disclose Phase 3 failure in DLBCL
AbbVie and Genmab reported that Epkinly (their antibody‑drug conjugate) failed to prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The companies said the...
UC San Diego wins ARPA‑H grant: $25.8M drive to 3D‑print patient livers
UC San Diego secured a $25,771,771 ARPA‑H award to develop patient‑specific, 3D‑bioprinted whole livers over a 60‑month program aimed at scalable, immunocompetent organ manufacture. The...
Vedanta trims workforce, narrows focus to VE303: phase‑3 push for C. difficile
Vedanta Biosciences said it significantly reduced headcount to concentrate remaining resources on VE303, its lead live‑biotherapeutic bacterial consortium for prevention of recurrent...
Labcorp expands MRD portfolio: Plasma Detect ID and Genome go nationwide
Labcorp launched two assays—Plasma Detect ID and Plasma Detect Genome—expanding its molecular residual disease (MRD) testing suite nationwide. The personalized whole‑exome sequencing‑guided Plasma...
Delfi eyes FDA: FirstLook Lung pivotal readouts and reimbursement push in 2026
Delfi Diagnostics outlined a 2026 roadmap of multiple pivotal data readouts for its FirstLook Lung liquid biopsy, aiming to support regulatory submission and commercial reimbursement. CEO Susan...
Novo Nordisk Foundation commits up to $850M: BioInnovation Institute to scale across Europe
The Novo Nordisk Foundation pledged up to $850 million to expand the BioInnovation Institute (BII) beyond Denmark and accelerate European life‑science startups. BII, spun out of the foundation,...
DNA fragments dodge screening: researchers show synthesis checks can be bypassed
A team led by Edison, Toner and Esvelt published a study demonstrating that assembling unregulated DNA fragments can circumvent current commercial DNA synthesis screening pipelines. The work,...
GT Biopharma files IND for TriKE — Medicenna advances MDNA‑113 toward IND
GT Biopharma filed an IND for GTB‑5550, a B7‑H3‑targeted TriKE intended for B7‑H3‑expressing solid tumors; the company plans a Phase 1 basket trial with subcutaneous dosing pending FDA clearance....
U.K. launches Synthetic Human Genome moonshot: £10M SynHG to build genome‑writing tools
A Wellcome‑funded five‑year Synthetic Human Genome (SynHG) consortium received £10 million to develop foundational technologies for large‑scale chromosome engineering, aiming to create reliable...
Off-the-shelf CAR‑NK: Durable complete responses in Waldenström’s
Early clinical data show ImmunityBio’s off-the-shelf CD19 CAR‑NK therapy produced durable complete responses in heavily pretreated Waldenström’s macroglobulinemia patients. Company reports — drawn...
ARPA‑H funds UC San Diego to 3D‑print patient livers
ARPA‑H awarded UC San Diego a $25.77 million, 60‑month grant to develop patient‑specific, 3D‑bioprinted human livers under the PRINT program. The multidisciplinary team will combine rapid...
Epkinly misses endpoint: No overall survival benefit in DLBCL study
AbbVie and Genmab reported that Epkinly failed to extend overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL) patients who had received at least one prior therapy. The...
Vedanta refocuses on VE303 — deep cuts to preserve Phase 3 runway
Vedanta Biosciences sharply reduced headcount and furloughed staff to concentrate remaining resources on its lead live‑biotherapeutic candidate VE303 and its Phase 3 program for recurrent...
Labcorp expands MRD and NGS offerings; Watchmaker, Saga add tools
Labcorp launched two new circulating tumor DNA assays — Plasma Detect ID (personalized whole‑exome guided panels) and Plasma Detect Genome (whole‑genome MRD) — to broaden its MRD portfolio across...
Novo Nordisk Foundation pledges up to $850M to scale European biotech
The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute beyond Denmark to a pan‑European reach. The funding will support early‑stage startups, scaling of...
SpyGlass, Agomab file IPOs after JPM — investor momentum continues
SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings following investor interest sparked at J.P. Morgan Healthcare Conference. Both drug developers aim to leverage the window...
EU grant backs Destina’s LiverAce assay for drug‑induced liver injury
Destina Genomica secured €2.2 million via an EIC funding stream to advance LiverAce Combo, a PCR‑free assay that measures RNA (miR‑122) and protein (CK‑18) biomarkers simultaneously for early...